Literature DB >> 30573663

HLA-DO Modulates the Diversity of the MHC-II Self-peptidome.

Padma P Nanaware1, Mollie M Jurewicz1, John D Leszyk2, Scott A Shaffer2,3, Lawrence J Stern4,3.   

Abstract

Presentation of antigenic peptides on MHC-II molecules is essential for tolerance to self and for initiation of immune responses against foreign antigens. DO (HLA-DO in humans, H2-O in mice) is a nonclassical MHC-II protein that has been implicated in control of autoimmunity and regulation of neutralizing antibody responses to viruses. These effects likely are related to a role of DO in selecting MHC-II epitopes, but previous studies examining the effect of DO on presentation of selected CD4 T cell epitopes have been contradictory. To understand how DO modulates MHC-II antigen presentation, we characterized the full spectrum of peptides presented by MHC-II molecules expressed by DO-sufficient and DO-deficient antigen-presenting cells in vivo and in vitro using quantitative mass spectrometry approaches. We found that DO controlled the diversity of the presented peptide repertoire, with a subset of peptides presented only when DO was expressed. Antigen-presenting cells express another nonclassical MHC-II protein, DM, which acts as a peptide editor by preferentially catalyzing the exchange of less stable MHC-II peptide complexes, and which is inhibited when bound to DO. Peptides presented uniquely in the presence of DO were sensitive to DM-mediated exchange, suggesting that decreased DM editing was responsible for the increased diversity. DO-deficient mice mounted CD4 T cell responses against wild-type antigen-presenting cells, but not vice versa, indicating that DO-dependent alterations in the MHC-II peptidome could be recognized by circulating T cells. These data suggest that cell-specific and regulated expression of HLA-DO serves to fine-tune MHC-II peptidomes, in order to enhance self-tolerance to a wide spectrum of epitopes while allowing focused presentation of immunodominant epitopes during an immune response.
© 2019 Nanaware et al.

Entities:  

Keywords:  Absolute quantification; Immunoaffinity; Immunology*; Label-free quantification; Mass Spectrometry; Peptidomics

Mesh:

Substances:

Year:  2018        PMID: 30573663      PMCID: PMC6398211          DOI: 10.1074/mcp.RA118.000956

Source DB:  PubMed          Journal:  Mol Cell Proteomics        ISSN: 1535-9476            Impact factor:   5.911


  77 in total

1.  H2-O, a MHC class II-like protein, sets a threshold for B-cell entry into germinal centers.

Authors:  Nicole A Draghi; Lisa K Denzin
Journal:  Proc Natl Acad Sci U S A       Date:  2010-08-31       Impact factor: 11.205

2.  Purification and characterization of class II histocompatibility antigens from a homozygous human B cell line.

Authors:  J C Gorga; V Horejsí; D R Johnson; R Raghupathy; J L Strominger
Journal:  J Biol Chem       Date:  1987-11-25       Impact factor: 5.157

3.  On the complexity of self.

Authors:  S Rath; P Preston-Hurlburt; D B Murphy; C A Janeway
Journal:  Nature       Date:  1991-10-17       Impact factor: 49.962

4.  Human monoclonal antibody with T-cell-like specificity recognizes MHC class I self-peptide presented by HLA-DR1 on activated cells.

Authors:  A Wölpl; T Halder; H Kalbacher; H Neumeyer; K Siemoneit; S F Goldmann; T H Eiermann
Journal:  Tissue Antigens       Date:  1998-03

5.  A role for HLA-DO as a co-chaperone of HLA-DM in peptide loading of MHC class II molecules.

Authors:  H Kropshofer; A B Vogt; C Thery; E A Armandola; B C Li; G Moldenhauer; S Amigorena; G J Hämmerling
Journal:  EMBO J       Date:  1998-06-01       Impact factor: 11.598

6.  Endogenous HLA class II epitopes that are immunogenic in vivo show distinct behavior toward HLA-DM and its natural inhibitor HLA-DO.

Authors:  Anita N Kremer; Edith D van der Meijden; Maria W Honders; Jelle J Goeman; Emmanuel J H J Wiertz; J H Frederik Falkenburg; Marieke Griffioen
Journal:  Blood       Date:  2012-08-13       Impact factor: 22.113

7.  Altered major histocompatibility complex class II peptide loading in H2-O-deficient mice.

Authors:  M Perraudeau; P R Taylor; H J Stauss; R Lindstedt; A E Bygrave; D J Pappin; S Ellmerich; A Whitten; D Rahman; B Canas; M J Walport; M Botto; D M Altmann
Journal:  Eur J Immunol       Date:  2000-10       Impact factor: 5.532

8.  H2-O expression in primary dendritic cells.

Authors:  Xinjian Chen; Lisa M Reed-Loisel; Lars Karlsson; Peter E Jensen
Journal:  J Immunol       Date:  2006-03-15       Impact factor: 5.422

9.  PTRF/cavin-1 and MIF proteins are identified as non-small cell lung cancer biomarkers by label-free proteomics.

Authors:  Angelo Gámez-Pozo; Iker Sánchez-Navarro; Enrique Calvo; María Teresa Agulló-Ortuño; Rocío López-Vacas; Esther Díaz; Emilio Camafeita; Manuel Nistal; Rosario Madero; Enrique Espinosa; Juan Antonio López; Juan Ángel Fresno Vara
Journal:  PLoS One       Date:  2012-03-26       Impact factor: 3.240

10.  Germinal center B cells regulate their capability to present antigen by modulation of HLA-DO.

Authors:  Kim S Glazier; Sandra B Hake; Helen M Tobin; Amy Chadburn; Elaine J Schattner; Lisa K Denzin
Journal:  J Exp Med       Date:  2002-04-15       Impact factor: 14.307

View more
  10 in total

Review 1.  Trial watch: dendritic cell vaccination for cancer immunotherapy.

Authors:  Jenny Sprooten; Jolien Ceusters; An Coosemans; Patrizia Agostinis; Steven De Vleeschouwer; Laurence Zitvogel; Guido Kroemer; Lorenzo Galluzzi; Abhishek D Garg
Journal:  Oncoimmunology       Date:  2019-07-18       Impact factor: 8.110

2.  Human Hepatitis B Viral Infection Outcomes Are Linked to Naturally Occurring Variants of HLA-DOA That Have Altered Function.

Authors:  Austin M Graves; Francesca Virdis; Eliot Morrison; Miguel Álvaro-Benito; Aly A Khan; Christian Freund; Tatyana V Golovkina; Lisa K Denzin
Journal:  J Immunol       Date:  2020-07-20       Impact factor: 5.422

3.  MHC-II alleles shape the CDR3 repertoires of conventional and regulatory naïve CD4+ T cells.

Authors:  Nadezhda N Logunova; Valeriia V Kriukova; Pavel V Shelyakin; Evgeny S Egorov; Alina Pereverzeva; Nina G Bozhanova; Mikhail Shugay; Dmitrii S Shcherbinin; Mikhail V Pogorelyy; Ekaterina M Merzlyak; Vasiliy N Zubov; Jens Meiler; Dmitriy M Chudakov; Alexander S Apt; Olga V Britanova
Journal:  Proc Natl Acad Sci U S A       Date:  2020-06-01       Impact factor: 11.205

4.  Genetic Control of Neonatal Immune Tolerance to an Exogenous Retrovirus.

Authors:  Emily Cullum; Stanislav Dikiy; Helen A Beilinson; Melissa Kane; Alessandra Veinbachs; Vera M Beilinson; Lisa K Denzin; Alexander Chervonsky; Tatyana Golovkina
Journal:  J Virol       Date:  2020-11-23       Impact factor: 5.103

Review 5.  The love and hate relationship of HLA-DM/DO in the selection of immunodominant epitopes.

Authors:  Robin A Welsh; Scheherazade Sadegh-Nasseri
Journal:  Curr Opin Immunol       Date:  2020-06-28       Impact factor: 7.486

6.  Synergy between B cell receptor/antigen uptake and MHCII peptide editing relies on HLA-DO tuning.

Authors:  Wei Jiang; Lital N Adler; Henriette Macmillan; Elizabeth D Mellins
Journal:  Sci Rep       Date:  2019-09-25       Impact factor: 4.379

7.  MHC Class II Presentation Is Affected by Polymorphism in the H2-Ob Gene and Additional Loci.

Authors:  Emily Cullum; Austin M Graves; Vera L Tarakanova; Lisa K Denzin; Tatyana Golovkina
Journal:  J Immunol       Date:  2021-06-16       Impact factor: 5.422

8.  Yeast display of MHC-II enables rapid identification of peptide ligands from protein antigens (RIPPA).

Authors:  Rongzeng Liu; Wei Jiang; Elizabeth D Mellins
Journal:  Cell Mol Immunol       Date:  2021-06-11       Impact factor: 11.530

Review 9.  How Does B Cell Antigen Presentation Affect Memory CD4 T Cell Differentiation and Longevity?

Authors:  Robin A Welsh; Nianbin Song; Scheherazade Sadegh-Nasseri
Journal:  Front Immunol       Date:  2021-06-10       Impact factor: 7.561

10.  Lack of the MHC class II chaperone H2-O causes susceptibility to autoimmune diseases.

Authors:  Robin A Welsh; Nianbin Song; Catherine A Foss; Tatiana Boronina; Robert N Cole; Scheherazade Sadegh-Nasseri
Journal:  PLoS Biol       Date:  2020-02-18       Impact factor: 8.029

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.